Loading clinical trials...
Loading clinical trials...
A Phase II Trial of Tazemetostat Plus Mosunetuzumab in Untreated Follicular Lymphoma
Conditions
Interventions
Mosunetuzumab
Tazemetostat Pill
Locations
1
United States
Weill Cornell Medicine/NewYork-Presbyterian Hospital
New York, New York, United States
Start Date
November 1, 2023
Primary Completion Date
October 1, 2033
Completion Date
October 1, 2033
Last Updated
April 2, 2026
NCT07545603
NCT06337318
NCT05006716
NCT06026319
NCT06510361
NCT07128641
Lead Sponsor
Weill Medical College of Cornell University
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions